What is the recommended naloxone dosing for opioid overdose in adults and children?

Naloxone Dosing for Opioid Overdose

For adults with suspected opioid overdose, administer an initial dose of 0.4 to 2 mg intravenously, intramuscularly, or subcutaneously, titrating to restore adequate ventilation—not full consciousness—to minimize precipitated withdrawal. 1

Adult Dosing

Initial Dose and Route Selection

• Intravenous administration provides the most rapid onset and is the preferred route in emergency situations where IV access is available 1
• The FDA-approved initial dose range is 0.4 to 2 mg IV/IM/SC, with repeat doses every 2-3 minutes if the desired respiratory improvement is not achieved 1
• Intranasal naloxone at 2 mg is the most commonly used initial dose for prehospital and community settings, though 0.4 mg intranasal has shown equal efficacy with fewer adverse effects in some studies 2, 3
• If no response occurs after 10 mg total naloxone, question the diagnosis of opioid toxicity 1

Titration Strategy

• The goal is restoration of adequate ventilation and respiratory rate—not full alertness—to avoid precipitating acute opioid withdrawal syndrome 1, 4
• For opioid-dependent patients, use low-dose naloxone (0.04 to 0.1 mg IV) with careful titration to reverse respiratory depression while preserving some analgesia 4
• Increments of 0.1 to 0.2 mg IV every 2-3 minutes are appropriate for postoperative opioid depression to balance reversal with analgesia 1

Fentanyl Considerations

• Fentanyl overdoses likely require higher naloxone doses than heroin due to fentanyl's high receptor affinity and potency 5
• Be prepared to administer multiple doses or continuous infusion for synthetic opioid overdoses 6

Pediatric Dosing

Children (≥5 years or ≥20 kg)

• Initial dose: 2 mg IV/IO/IM/SC for suspected opioid overdose 7
• If IV access is unavailable, administer IM or SC in divided doses 1

Young Children (<5 years or <20 kg)

• Initial dose: 0.1 mg/kg IV/IO/IM/SC for suspected opioid overdose 7, 1
• If this dose fails to produce clinical improvement, a subsequent dose of 0.1 mg/kg may be administered 1

Neonates

• Initial dose: 0.01 mg/kg IV/IM/SC for opioid-induced respiratory depression 1
• Do NOT administer naloxone to newborns whose mothers have chronic opioid use due to risk of seizures and acute withdrawal 7
• For postoperative depression, use increments of 0.005 to 0.01 mg IV every 2-3 minutes 1

Critical Monitoring and Re-dosing

Observation Period

• Patients must be observed for at least 3 hours after the last naloxone dose because naloxone's duration of action (45-70 minutes) is markedly shorter than most opioids 6, 5
• The American Heart Association gives Class I (highest level) recommendation for extended observation until vital signs normalize and risk of recurrent toxicity is low 6

Signs Requiring Re-dosing

• Monitor continuously for re-sedation: decreasing respiratory rate, falling oxygen saturation, altered mental status 6
• Repeat naloxone doses or initiate continuous infusion (2 mg in 500 mL normal saline = 0.004 mg/mL) if re-sedation occurs 6, 1
• Airway protection and ventilatory support take precedence over additional naloxone if airway is compromised 6

Common Pitfalls and Caveats

Withdrawal Precipitation

• Excessive naloxone dosing precipitates acute opioid withdrawal with nausea, vomiting, agitation, tachycardia, and hypertension 1, 4
• The 0.4 mg intranasal dose produces significantly fewer adverse effects (2.1%) compared to 2 mg (29%) while maintaining equal efficacy 3

Duration Mismatch

• Naloxone's effect duration (2 hours for 1 mg IV) is shorter than most opioids, particularly long-acting formulations and fentanyl analogs 6, 5
• Patients may appear recovered then re-sedate after naloxone wears off—this is the primary reason for mandatory observation 6

Route-Specific Considerations

• Intranasal bioavailability is approximately 50% with slower uptake (Tmax 15-30 minutes) compared to IM administration 5
• Intramuscular or subcutaneous routes provide longer-lasting effect than IV and should be considered when available 1
• Endotracheal administration is not recommended for newborns 7

Discharge Criteria

Patients may be discharged only when ALL of the following are met:

• At least 3 hours have elapsed since final naloxone dose without recurrence of symptoms 6
• Stable vital signs with normal oxygen saturation and respiratory rate throughout observation 6
• Sustained normal level of consciousness (GCS 15) 6
• Provision of take-home naloxone kit and overdose prevention education 6